– MyCare™ Insite Clozapine Test levert binnen 6 minuten resultaten op met behulp van een druppel bloed van een vinger, waardoor artsen geïnformeerde, geïndividualiseerde zorgplannen kunnen ontwikkelen op de behandelplaats (POC).
– Dit is de eerste en enige snelle point-of-care-test met CE-markering die beschikbaar is om professionals in de geestelijke gezondheidszorg te helpen bij de behandeling en monitoring van patiënten met psychose.
BETHLEHEM, Pa.-(BUSINESS WIRE)-Saladax Biomedical heeft aangekondigd dat de MyCare Insite Clozapine Test nu CE-gemarkeerd is voor gebruik op de MyCare Insite. De MyCare Insite Clozapine Test is de eerste en enige snelle point-of-care test die CE gemarkeerd is om professionals in de geestelijke gezondheidszorg te helpen bij de behandeling en monitoring van patiënten met schizofrenie.
Saladax Develops First-Ever Rapid Test for an Antipsychotic Drug Using a Single Drop of Blood to Aid Psychiatrists in the Treatment of Schizophrenia
– MyCare™ Insite Clozapine Test provides results in 6 minutes using a drop of blood from a finger stick enabling clinicians to develop informed, individualized care plans at the point of care (POC).
– This is the first and only rapid point-of-care test available with CE mark to aid mental health professionals in the treatment and monitoring of patients with psychosis.
BETHLEHEM, Pa.–(BUSINESS WIRE)– Saladax Biomedical today announced that its MyCare Insite Clozapine Test is now CE marked for use on the MyCare Insite. The MyCare Insite Clozapine Test is the first and only rapid point-of-care test CE marked to aid mental health professionals in the treatment and monitoring of patients with schizophrenia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190905005085/en/
The MyCare Insite Clozapine Test delivers accurate and precise clozapine blood levels comparable to laboratory results. Psychiatrists need immediate information to make informed decisions during a patient visit. The MyCare Insite Clozapine Test addresses this unmet medical need by providing answers in only six minutes. Clinicians, in consultation with their patients, can use these results to make real-time adjustments to better manage their patients.
“Mental health professionals have very few tools to aid in patient treatment; as a result, patients are suffering. The MyCare Insite Clozapine Test provides clinicians a first of its kind device. The test is evidence of how Saladax is once again setting new standards for innovation in the treatment and monitoring of patients,” said Dr. Salvatore Salamone, CEO and Founder of Saladax Biomedical. “We are changing psychiatry with a single drop of blood.”
Psychosis is a condition that affects the way your brain processes information. It causes you to lose touch with reality. Psychotic disorders, like schizophrenia, involve psychosis that usually affects you for the first time in the late teen years or early adulthood. Young people are especially at risk, but doctors don’t know why.
ABOUT THE MyCARE INSITE CLOZAPINE TEST
The MyCare Insite Clozapine Test is intended for the in vitro quantitative measurement of clozapine in human capillary finger blood using the MyCare Insite.
Founded in 2004, Saladax Biomedical, Inc. is a privately held company headquartered as an anchor tenant at Ben Franklin TechVentures® located on Lehigh University’s campus in Bethlehem, PA.
Saladax develops rapid blood tests for point-of-care and for laboratory analysers for use in psychiatry and oncology. The Saladax MyCare Psychiatry line provides drug levels for greater insight into patient adherence and possible causes of treatment failures. These tests enable psychiatrists to more accurately assess adherence and better adjust medication dosing. Saladax believes that truly personalized medicine can only exist when the right drug is taken at the right dose. Our diagnostic reagent kits are distributed worldwide and are pending approval in the United States. Saladax is ISO 13485:2016 certified.
Saladax Biomedical, Inc.
Salvatore Salamone, Ph.D., 610-419-6731@NewsNovumpr